Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-04-12
2011-04-12
Saunders, David A (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07923215
ABSTRACT:
The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 3991210 (1976-11-01), Shea
patent: 4129666 (1978-12-01), Wizerkaniuk
patent: 4339431 (1982-07-01), Gaffar
patent: 4594409 (1986-06-01), Hayashi et al.
patent: 5204099 (1993-04-01), Barbier et al.
patent: 5554372 (1996-09-01), Hunter et al.
patent: 5583031 (1996-12-01), Stern
patent: 5591629 (1997-01-01), Rodriguez et al.
patent: 5623052 (1997-04-01), McLean et al.
patent: 5627206 (1997-05-01), Hupe et al.
patent: 5668117 (1997-09-01), Shapiro
patent: 5716946 (1998-02-01), DeLuca et al.
patent: 5719296 (1998-02-01), Acton, III et al.
patent: 5734023 (1998-03-01), Nag et al.
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5886156 (1999-03-01), McLean et al.
patent: 5958972 (1999-09-01), Hupe et al.
patent: 5965600 (1999-10-01), Sato et al.
patent: 5981589 (1999-11-01), Konfino et al.
patent: 6024981 (2000-02-01), Khankari et al.
patent: 6048898 (2000-04-01), Konfino et al.
patent: 6054430 (2000-04-01), Konfino et al.
patent: 6162800 (2000-12-01), Dolle et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6362161 (2002-03-01), Konfino et al.
patent: 6369099 (2002-04-01), DeLuca et al.
patent: 6514938 (2003-02-01), Gad et al.
patent: 6620847 (2003-09-01), Konfino et al.
patent: 6800285 (2004-10-01), Rodriguez et al.
patent: 6800287 (2004-10-01), Gad et al.
patent: 6844314 (2005-01-01), Eisenbach-Schwartz
patent: 6855270 (2005-02-01), Mumper et al.
patent: 6939539 (2005-09-01), Konfino et al.
patent: 7022663 (2006-04-01), Gilbert et al.
patent: 7033582 (2006-04-01), Yong et al.
patent: 7074580 (2006-07-01), Gad et al.
patent: 7163802 (2007-01-01), Gad et al.
patent: 7199098 (2007-04-01), Konfino et al.
patent: 7279172 (2007-10-01), Aharoni et al.
patent: 7407936 (2008-08-01), Eisenbach-Schwartz et al.
patent: 7425332 (2008-09-01), Aharoni et al.
patent: 7429374 (2008-09-01), Klinger
patent: 7495072 (2009-02-01), Dolitzky et al.
patent: 7566767 (2009-07-01), Strominger et al.
patent: 2002/0037848 (2002-03-01), Eisenbach-Schwartz et al.
patent: 2002/0107388 (2002-08-01), Vandenbark
patent: 2003/0170729 (2003-09-01), Klinger
patent: 2004/0006022 (2004-01-01), Strominger et al.
patent: 2005/0170004 (2005-08-01), Rosenberger et al.
patent: 2006/0052586 (2006-03-01), Dolitzky et al.
patent: 2006/0122113 (2006-06-01), Pinchasi et al.
patent: 2006/0172942 (2006-08-01), Dolitzky
patent: 2006/0240463 (2006-10-01), Lancet
patent: 2006/0264354 (2006-11-01), Aharoni
patent: 2007/0021324 (2007-01-01), Dolitzky
patent: 2007/0021341 (2007-01-01), Sela et al.
patent: 2007/0048794 (2007-03-01), Gad et al.
patent: 2007/0054857 (2007-03-01), Pinchasi et al.
patent: 2007/0059798 (2007-03-01), Gad et al.
patent: 2007/0173442 (2007-07-01), Vollmer et al.
patent: 2002353059 (2008-10-01), None
patent: 2469393 (2010-05-01), None
patent: DE3930733 (1991-03-01), None
patent: 0383620 (1990-08-01), None
patent: 0359783 (1995-11-01), None
patent: 1292279 (2003-03-01), None
patent: 0378246 (2003-06-01), None
patent: 1459065 (2010-07-01), None
patent: 254496 (1990-08-01), None
patent: 336690 (1998-01-01), None
patent: 1690368 (1995-08-01), None
patent: 1469826 (1995-11-01), None
patent: 1182051 (1985-09-01), None
patent: 1664845 (1991-06-01), None
patent: WO 88/10120 (1988-12-01), None
patent: WO 92/02543 (1992-02-01), None
patent: WO 94/03484 (1994-02-01), None
patent: WO 94/26774 (1994-11-01), None
patent: WO 95/26980 (1995-10-01), None
patent: WO 95/31990 (1995-11-01), None
patent: WO 95/31997 (1995-11-01), None
patent: WO 95/33475 (1995-12-01), None
patent: WO 98/30227 (1998-07-01), None
patent: WO 00/05250 (2000-02-01), None
patent: WO0005249 (2000-02-01), None
patent: WO 00/18794 (2000-04-01), None
patent: WO 00/20010 (2000-04-01), None
patent: WO 00/27417 (2000-05-01), None
patent: WO0152878 (2001-07-01), None
patent: WO0160392 (2001-08-01), None
patent: WO0185797 (2001-11-01), None
patent: WO0193828 (2001-12-01), None
patent: WO0193893 (2001-12-01), None
patent: WO0197846 (2001-12-01), None
patent: WO02076503 (2002-10-01), None
patent: WO03048735 (2003-06-01), None
patent: WO2004043995 (2004-05-01), None
patent: WO2005041933 (2005-05-01), None
patent: WO2006050122 (2006-05-01), None
patent: WO 2006/116602 (2006-11-01), None
patent: WO2008006026 (2008-01-01), None
patent: SA980214 (1999-09-01), None
U.S. Appl. No. 09/359,099, filed Jul. 22, 1999, Strominger et al.
Abramsky, et al., “Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis”, J. Neurol. Sci., 1977, 31, 433-438.
Aharoni, R. et al., (1993) “T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer I or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis”, Eur. J. Immunol., vol. 23, pp. 17-25.
Aharoni, et al., “Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease”, Immunol. Letters, 1997, 58, 79-87.
Aharoni (1997) “Copolymer 1 Induces T Cells of the T Helper Type 2 that Crossreact with Myelin Basic Protein and Suppress Experimental Autoimmune Encephalomyelitis”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 10821-10826.
Aharoni, et al., “Cop 1 Specific Suppressor Cells Inhibit Experimental Allergic Encephalomyelitis Induced by Either Mouse Spinal Cord Homogenate or Proteolipid Protein Peptide 139-151”, Neurology, 1997, vol. 48, No. 3, A422.
Aharoni, R. et al., (1998) “Bystander Suppression of Experimental Autoimmune Encephalomyelitis by T cell Lines and Clones of the Th2 Type Induced by Copolymer 1”, Journal of Neuroimmunology, vol. 91, No. 1-2, pp. 135-146.
Aharoni, et al., “Copolymer 1 Inhibits Manifestations of Graft Rejection”, Transplantation, 2001, vol. 72, No. 4, 598-605.
Alvord, et al., “Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys”, Ann. Neurol., 1979, 6, 469-473.
Arnon, et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen”, Israel J. Med. Sci., 1972, 8, 1759-1760 (Abstract).
Arnon, et al., “Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids”, Neurol., 1978, 28, 336 (Abstract).
Arnon, “A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy”, Progress in Multiple Sclerosis Research (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418.
Arnon, et al., “Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues”, The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis (Academic Press, New York, 1980) 105-107.
Arnon, “Experimental Allergic Encephalomyelitis—Susceptibility and Suppression”, Immunological Rev., 1981, 55, 5-30.
Arnon, et al., “Suppression of Demyelinating Diseases by Synthetic Copolymers”, A Multidisciplinary Approach to Myelin Disease (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250.
Arnon, et al., “Suppression of Experimental Allergic Encephalomyelitis by Cop-1—Relevance to Multiple Sclerosis”, Israel J. Med. Sci., 1989, 25, 686-689.
Arnon, et al., “On the Existence of Suppressor Cells”, Int. Arch. Allergy Immunol., 1993, 100, 2-7.
Arnon, et al., “Immunomodulation of Experimental Allergic Encephalomyelitis”, Israel J. Med. Sci., 1993, 29, 175-181.
Arnon, et al., “Immunospecific Drug Design—Prospects for Treatment of Autoimmune Disease”, Therapeutic Immunol., 1994, 1, 65-70.
Asakura and Rodriguez, “A Unique Populatio
Cooper & Dunham LLP
Saunders David A
Teva Pharmaceutical Industries Ltd.
White John P.
LandOfFree
Process for the measurement of the potency of glatiramer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the measurement of the potency of glatiramer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the measurement of the potency of glatiramer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2738592